ALCOHOLIC HEPATITIS TREATMENT MARKET ANALYSIS

Alcoholic Hepatitis Treatment MarketSize and Trends

Global Alcoholic Hepatitis Treatment Market – Dynamics

The rising cases of alcohol use and deaths due to alcoholic hepatitis are expected to propel the growth of global alcoholic hepatitis treatment market over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2018, 25.1% of adults aged 18 and above had at least one heavy drinking day (five or more drinks for men and four or more drinks for women) in the U.S. Moreover, in 2019, 24,110 people died as a result of alcoholic liver disease in the U.S.

Moreover, increasing product launches and approvals is expected to boost global alcoholic hepatitis treatment market growth. For instance, on December 16, 2020, Durect Corporation announced that DUR-928 was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of alcoholic hepatitis. Durect is a biopharmaceutical company dedicated to transforming the treatment of acute organ injury and chronic liver diseases through the development of novel, potentially lifesaving therapies. DUR-928, Durect's lead drug candidate, is an endogenous sulfated oxysterol and an epigenetic regulator with a distinct mechanism of action. Epigenetic regulators are compounds that control gene expression patterns without altering the DNA sequence. These factors are expected to support global alcoholic hepatitis treatment market growth over the forecast period.